Your session is about to expire
← Back to Search
Insulin Delivery System
Insulin-alone closed-loop for Type 1 Diabetes
N/A
Waitlist Available
Led By Laurent Legault, MD
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 40-hour intervention
Awards & highlights
Study Summary
This study is evaluating whether a new insulin dosing algorithm is safe for children with type 1 diabetes.
Eligible Conditions
- Type 1 Diabetes
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 40-hour intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~40-hour intervention
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Time in range
Secondary outcome measures
Coefficient of variance of glucose levels and insulin delivery
Mean glucose levels
Specific nighttime time in range
+3 moreSide effects data
From 2016 Phase 4 trial • 85 Patients • NCT0197024121%
Hypoglycemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
NPH With Corticosteroid
Control
Trial Design
1Treatment groups
Experimental Treatment
Group I: Insulin alone closed-loopExperimental Treatment1 Intervention
Insulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.
Find a Location
Who is running the clinical trial?
McGill UniversityLead Sponsor
394 Previous Clinical Trials
998,367 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,618 Previous Clinical Trials
3,201,550 Total Patients Enrolled
Laurent Legault, MDPrincipal InvestigatorMontreal Children's Hospital of the MUHC
3 Previous Clinical Trials
70 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger